

REVIEW Article

Blood Transfusion in the 21st Century

Mark T. Friedman^{1,*}, Vaidehi Avadhani¹, Sandra Gilmore², Emilio Madrigal¹

¹Department of Pathology, Blood Bank and Transfusion Services, ²Blood Management, Bloodless Medicine and Surgery, Mount Sinai Health System, St. Luke's, Roosevelt, and Beth Israel Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY 10019, USA

Corresponding author: Mark T. Friedman, DO, Mount Sinai Roosevelt Hospital, Medical Director of Blood Bank and Transfusion Service, 1000 Tenth Avenue, New York, NY 10019. Phone: 212-523-7242; Fax: 212-523-6394; markfriedman@chpnet.org.

Submitted: March 11, 2014; *Published after revision:* March 31, 2014;

Citation: Friedman MT, Avadhani V, Gilmore S, Madrigal E. Blood Transfusion in the 21st Century. Discoveries 2014, Jan-Mar; 2(1): e11. DOI: 10.15190/d.2014.3

ABSTRACT

Blood transfusion is a common procedure in the hospital setting, and the safety of the blood supply has been vastly improved over the past few decades largely due to improvements in screening for viral transmissible diseases, especially human immunodeficiency virus (HIV) and viral hepatitis. However, more recent efforts to improve blood safety have focused on non-transmissible disease risks such as transfusion-related acute lung injury (TRALI), non-viral transmissible diseases such as bacterial contamination of blood products (especially platelet components which are stored at room temperature) and Chagas disease (a parasitic disease caused by *Trypanosoma cruzi*), and prion transmissible agents (e.g., variant Creutzfeldt-Jakob disease, also known as the agent of mad cow disease) as well as more recently-recognized transmissible viral disease risks such as West Nile virus. Appropriate blood utilization has also come under more intense scrutiny in recent times due to healthcare costs and the recognition that many blood transfusions are given under circumstances in which the benefit to the patients is unclear and may be potentially harmful due to the above risks as well as the emerging concept that blood transfusions may cause long-term damage to the immune system resulting in worse patient morbidity and mortality outcomes. Toward that end, accreditation agencies such as the Joint Commission and the American Association of Blood Banks (AABB) are advocating for healthcare organizations to

implement appropriate patient blood management strategies. This review will examine these issues along with newer blood safety technological innovations and further highlight contributing studies from our institutions.

Keywords: Blood substitutes; factor concentrates; hemovigilance; patient blood management; transfusion medicine education; transfusion safety.

Abbreviations

American Association of Blood Banks (AABB); Centers for Disease Control and Prevention (CDC); Cytomegalovirus (CMV); Food and Drug Administration (FDA); Hemoglobin-based oxygen carriers (HBOC's); Human immunodeficiency virus (HIV); Human leukocyte antigen (HLA); Patient blood management (PBM); Perfluorocarbons (PFC's); Serious Hazards of Transfusion (SHOT); The Joint Commission (TJC); Transfusion-associated graft-vs-host disease (TA-GVHD); Transfusion-related acute lung injury (TRALI); Transfusion-related immunomodulation (TRIM); United Kingdom (U.K.); Variant Creutzfeldt-Jakob disease (vCJD).

SUMMARY

1. Introduction
2. Safety of the blood supply
3. Quality of the blood supply
4. Transfusion medicine education
5. Patient blood management
6. Future technology
7. Concluding remarks

1. Introduction

Blood transfusion is one of the most common procedures performed in hospitals. Accordingly, it was reported that there were nearly 15 million whole blood and red blood cell units transfused in the United States alone in 2008, representing a nearly 6% increase in transfusions from the prior surveyed year of 2006¹. This is because anemia is a common comorbidity that can be found in a variety of patients, including patients with cancer, patients undergoing surgical procedures or hemodialysis, patients with autoimmune or bone marrow disorders (such as myelodysplastic syndrome), patients with congenital anemia (such as sickle cell anemia and thalassemia), trauma patients, obstetrical patients, and patients with nutritional deficiencies, such as iron deficiency. While it is certainly known that anemia can have adverse effects on patients, particularly in cardiovascular and neurocritical care patients²⁻⁴, what is becoming more evident is that correction of anemia via blood transfusion is not beneficial to many patients, and in fact, may be more harmful, unless the patient is acutely symptomatic (e.g., shortness of breath, low blood pressure, rapid heart rate, dizziness, or chest pain) from the anemia. Thus, it is considered problematic that many blood transfusions are administered unnecessarily, driving up healthcare costs, expending a valuable resource (i.e., blood components) in short supply (because only a minority of eligible blood donors in the U.S. give blood), and exposing patients to all the risks and complications (like fluid and iron overload) of blood transfusions. Hébert et al. published their landmark study 15 years ago which demonstrated the lack of benefit of a liberal transfusion strategy over that of a restrictive one in critical care patients⁵. Since then, additional studies have been published demonstrating similar outcomes in other patient populations such as elderly patients undergoing orthopedic (e.g., hip replacement) surgery, pediatric patients, and patients with gastrointestinal bleeding⁶⁻⁸. Despite these data supportive of restrictive transfusion strategies along

Although blood transfusions are commonly used to treat anemia, restrictive transfusion practices (i.e., fewer transfusions) have been shown to be as effective if not better than liberal transfusion practices.

with the fact that published transfusion guidelines have been updated over the years to reflect a more conservative approach to blood utilization^{9,10}, clinicians have been slow to adopt these transfusion practices and in many cases, transfusion practices remain inconsistent even amongst physicians of the same specialty practicing within a localized region or even within the same institution¹¹. This review will further discuss issues surrounding blood utilization, including the safety and quality of the blood supply and patient blood management.

2. Safety of the blood supply

Over the years, the safety of the blood supply has dramatically improved. Early efforts to reduce risk focused on reliance on volunteer donors while screening out donors with high-risk behavior, such as male-to-male sex, for human immunodeficiency virus (HIV) and viral hepatitis (hepatitis B and hepatitis C) as well as the implementation of highly-sensitive testing to reduce the infectious window period, that is, the time between exposure to viral infection and ability of the blood test to detect the virus when the donor may be infectious though the test result is negative. Such strategies have reduced the risk of HIV and hepatitis C transmission through blood to about 1 in 2 million (or roughly the equivalent of the risk of getting struck by lightning)¹². More recently, testing for West Nile virus and Chagas disease (*Trypanosoma cruzi*) has been added to address those emerging transmissible disease threats to the blood supply^{13,14}, and standards were adopted for reducing the risk of bacterial contamination of platelet components (which must be stored at room temperature to maintain platelet hemostatic function)¹⁵. Still, there remain transmissible disease risks that are not tested for owing to the fact that U.S. Food and Drug Administration (FDA)-approved testing is unavailable. Perhaps most problematic in the U.S. is babesiosis, a parasitic agent that infects red blood cells à-la malaria but that is endemic in the northeastern U.S.; transmission of babesiosis through blood has been reported¹⁶, and the FDA may consider implementation of testing in the near future. Yet another transmissible agent for which testing is unavailable is variant Creutzfeldt-Jakob disease (vCJD, the prion agent of bovine spongiform encephalopathy or mad cow disease); human cases have been attributed to transfusion of blood

components in the United Kingdom¹⁷. To address this, prospective blood donors in the U.S. who have traveled for a defined period of time to the U.K. (cumulative 3 month travel between 1980 and 1996) or western Europe (cumulative 5 years between 1980 and present) are currently excluded; however, this is problematic as a number of otherwise-eligible blood donors are unable to donate, representing a small but not insignificant loss of U.S. blood donors¹⁸. Transfusion-transmitted cases of hepatitis E virus have also been reported outside of the U.S., though testing for this agent is not currently performed either¹⁹.

As the risk of transmissible disease through blood transfusion has decreased, non-infectious risks have become more prominent. Transfusion-related acute lung injury (TRALI), defined as edema or fluid collection in the lungs during or shortly (within 6 hours) after transfusion not causally-linked to heart failure or other cause of lung injury unrelated to transfusion such as pneumonia, has been shown to be largely a result of antibodies to white blood cell antigens (known as human leukocyte antigen [HLA] antibodies) in female donors (because of exposure to HLA during pregnancy); as a result, the use of plasma components (which contain the HLA antibodies) from females has been restricted in the U.S. unless the female donor is known not to have ever been pregnant or is otherwise tested for the causative HLA antibodies since last pregnancy²⁰. Transfusion of group ABO-incompatible blood is another non-infectious risk that has gained more recognition over time and is almost always due to human error such as error in collection of the crossmatch sample (i.e., the sample is collected from the wrong patient though labeled with the correct patient's identification) or in patient identification at the time of blood transfusion (i.e., blood correctly crossmatched but given to wrong patient). Strategies to reduce this risk have been

implemented by most hospital transfusion services, such as the requirement for a second sample to confirm the ABO blood type prior to crossmatch and strict blood administration policies for bedside patient identification at the time of transfusion. Nevertheless, TRALI and group ABO-incompatible transfusion occurrence estimates remain much greater than for transmission of HIV and hepatitis and are amongst the highest causes of transfusion-related fatalities^{21,22}. Transfusion-associated graft-vs.-host disease (TA-GVHD) is yet another non-infectious complication of transfusion that is fatal²³. However, though it is preventable through blood component irradiation which inactivates the causative immune cells (T4 lymphocytes), clinicians do not always order, or otherwise provide the patient's condition to alert the hospital blood bank to prepare, irradiated blood for their at-risk patients (those who are immunocompromised or have certain conditions like leukemia or Hodgkin's disease). Most hospital blood banks do not routinely maintain large inventories of irradiated blood since the irradiation process reduces the storage shelf life of the red blood cell products, nor do they have a blood irradiator device onsite which requires a significant amount space and carries a very high level of security concern to protect the radiation source²⁴. Finally, in addition to all the above risks, blood transfusion can lead to the formation of unexpected alloantibodies to red blood cell antigens (i.e., non-ABO antibodies such as antibodies to the Rh blood group system) in recipients which can make future blood transfusions even more difficult in the way of finding compatible blood and result in hemolytic reactions (because of incompatibility related to the unexpected antibodies) as well as carrying the added risk in females of childbearing age of causing severe complications, even fetal death, during pregnancy (i.e., hemolytic disease of the fetus and newborn)²⁵.

In order to further improve blood safety across the nation, the U.S. Biovigilance Network, a collaboration between the U.S. Department of Health and Human Services, including the Centers for Disease Control and Prevention (CDC), and organizations that collect and transfuse blood, launched the National Hemovigilance Program in 2010²⁶. The U.S. program followed that of many other developed countries, including France (where it was set into law by 1993) and the U.K.'s Serious

- Improved donor screening and transmissible disease testing, particularly for HIV and hepatitis C, vastly increased the safety of the blood supply.
- More recent efforts to increase safety have largely focused on noninfectious risks and bacterial contamination of blood products.




Figure 1: Transfusion safety schematic

Hazards of Transfusion (SHOT) program (which began in 1996)²⁷. The International Hemovigilance Network defines hemovigilance as “surveillance procedures covering the whole transfusion chain, from collection of blood and its components to follow-up of recipients, intended to collect and assess information on unexpected or undesirable effects resulting from the therapeutic use of labile blood products and to prevent their occurrence or

recurrence.”²⁷ However, many hospital transfusion services across the U.S. have been slow to join the reporting system which remains voluntary, limiting its effectiveness. Transfusion services are required, however, to report serious reactions, especially those that result in fatality, to the FDA as well as to their local department of health in a number of states²⁸⁻³⁰. A transfusion safety schematic is presented in Figure 1.

3. Quality of the blood supply

Efforts have been put forth to improve the quality of the blood supply in other areas. One major improvement resulted when the system of labeling blood components converted from Codabar symbology to the ISBT 128 system which has the advantage of being a global system that is unique, comprehensive, and more accurate in its coding method³¹. A second major improvement has resulted from the trend toward universal leukoreduction, or depletion of white blood cells, from blood components. However, universal leukoreduction in the U.S. has lagged behind Europe and Canada which implemented leukoreduction much earlier partly in response to the risk of vCJD transmission (vCJD has been reported to be closely associated with the buffy-coat or white blood cell layer of blood though more recent evidence has shown infectivity in plasma and red blood cells)³². White blood cells, considered contaminants of red blood cell and platelet components, pose complications related to febrile transfusion reactions, alloimmunization (i.e., formation of HLA antibodies which can lead to transplant rejection), and transmission of some pathogens like cytomegalovirus (CMV, a common herpes virus that may cause complications like pneumonia in some at-risk patients such as those who are immunocompromised). Yet it is unclear what impact leukoreduction at the time of collection (i.e., pre-storage leukoreduction), which removes about 99% of the white blood cells and prevents buildup of white cell products (known as cytokines) during storage, will have on the mitigation of transfusion-related immunomodulation (TRIM). TRIM is the concept that blood transfusions weaken the immune system in recipients and increase the risk of postoperative infections and cancer recurrence³³. Finally, there is some evidence that transfusion of older (greater than 14 days in storage) blood products compared with fresher ones (less than 14 days in storage) may also increase the risk of poorer hospital outcomes in some patient populations³⁴.

4. Transfusion medicine education

Unfortunately, in light of the above risks and complications of blood transfusion, clinicians continue to receive little to no formal training in appropriate use of blood products and their

practices continue to be principally based upon individual clinical experience³⁵. In fact, assessment of overall transfusion medicine knowledge in our own hospital facilities showed poor baseline knowledge amongst physicians across different specialties and training levels³⁵. As previously commented on in a published editorial, lack of transfusion medicine knowledge may possibly be the greatest obstacle toward making transfusion practices more consistent and in line with published guidelines and evidence-based medicine³⁶.

5. Patient blood management

Patient blood management (PBM), as defined by the AABB, is “an evidence-based, multidisciplinary approach to optimizing the care of patients who might need transfusion. PBM encompasses all aspects of patient evaluation and clinical management surrounding the transfusion decision-making process, including the application of appropriate indications, as well as minimization of blood loss and optimization of patient red cell mass. PBM can reduce the need for allogeneic blood transfusions and reduce health-care costs, while ensuring that blood components are available for the patients who need them.”³⁷ In addition to the AABB, the Joint Commission (TJC), a major organization that accredits healthcare organizations (formerly known as the Joint Commission on Accreditation of Healthcare Organizations or JCAHO), has drafted its own set of guidelines for PBM certification³⁸. Previously, though, TJC published a set of blood management performance measures that hospital transfusion services could opt to use to improve their processes surrounding transfusion³⁹. Measure PBM-02 RBC Transfusion Indication³⁹ was in part developed around published data from our hospitals showing a significant correlation between lack of transfusion documentation in the patient medical record and failure to justify the transfusion as clinically necessary⁴⁰. Transfusion services employ this measure to evaluate their blood utilization practices⁴¹, and we are currently planning a follow-

PBM strategies such as: preoperative anemia management, use of surgical techniques to minimize blood loss, or recover shed blood (intraoperative cell salvage), can minimize the need for blood transfusions.

up analysis in our own facilities. We further published data from our hospital facilities concerning Measure PBM-01 Transfusion Consent³⁹ demonstrating that information discussed with patients prior to transfusions tended to focus on the benefits of transfusion (namely, correction of anemia, which as noted above, may not actually be a benefit unless symptomatic) along with minor risks (such as febrile and allergic reactions) while omitting discussion of more significant risks such as hemolytic (incompatible blood) reactions, TRALI, volume overload, and transmission of HIV and hepatitis C⁴². PBM-01 is an important measure in that AABB standards require transfusion consent and in that the Institute of Medicine, in naming patient centeredness (defined as “providing care that is respectful of and responsive to individual patient preferences, needs, and values, and ensuring that patient values guide all clinical decisions”) as one of its 6 core attributes of a high-quality healthcare system, encourages dialogue between physicians and patients in the decision-making process⁴³.

6. Future technology

Although PBM strategies should optimize and in many instances minimize the use of blood transfusions as such strategies gain prominence in hospitals throughout the U.S. over time, the need for blood will be ever present largely because of an aging population that is expanding and undergoing more medical procedures, including cardiothoracic surgery, joint replacement, transplant surgery, hemodialysis, and cancer treatment (chemo- and radiation therapy), which will require transfusion support in many cases. Yet the promise of blood substitutes, also known as “artificial blood”, which are really oxygen therapeutic agents rather than complete substitutes for blood, has proven to be quite elusive. Development of a therapeutic oxygen carrier, which ideally would be readily available, universally compatible, pathogen free, cost efficient with minimal side effects and a long shelf life, has taken two forms over the years: perfluorocarbon emulsions (PFC’s) and hemoglobin-based oxygen carriers (HBOC’s)^{44,45}. PFC’s are chemically-inert, colorless, clear liquids that have the ability to dissolve large volumes of gases, including oxygen and carbon dioxide⁴⁴. However, PFC’s are also water insoluble and must be emulsified for

intravenous use, limiting their effectiveness due to low PFC content such that high concentrations of supplemental oxygen must be given in order to achieve a therapeutic effect. Fluosol-DA (Green Cross Corp., Osaka, Japan/Alpha Therapeutic, Los Angeles, CA), a first-generation PFC, received FDA approval in 1989 for use in coronary balloon angioplasty but was withdrawn from the market just 5 years later since it was found to be cumbersome to store (requiring frozen storage) and prepare for therapeutic use as well as the fact that improvements in angioplasty catheter technology eliminated the need for Fluosol^{45,46}. Second generation PFC’s, which have higher PFC content, such as Oxygent (Alliance Pharmaceutical Corp., La Jolla, CA) and Oxyfluor (Hemagen, Inc., St. Louis, MO) were subsequently developed and tested but have not been approved by the FDA^{45,46}. HBOC’s, on the other hand, are manufactured from human or bovine hemoglobin, and at least one recombinant (genetically-engineered) product was developed^{45,47}. However, the main obstacle to the

Blood substitutes, really oxygen therapeutic agents, though in development for many years are not approved for use in the U.S. and cannot replace the need for blood.

success of HBOC’s has been the fact that cell-free hemoglobin is quite toxic, causing increased vasoconstriction and vascular resistance leading to hypertension (due to scavenging of nitric oxide along the endothelial lining of the blood vessels where NO normally promotes vascular dilatation) and damage to the kidneys as well as gastrointestinal, hepatic, pancreatic, and neurological side effects⁴⁷. In addition, HBOC’s have a rather short plasma half-life and have altered oxygen-binding properties⁴⁵. Manufacturers have introduced various alterations to their proprietary HBOC’s in order to stabilize the cell-free hemoglobin and circumvent these problems including, intramolecular crosslinking, polymerization, pegylation, pyridoxilation, and encapsulation^{45,46}. As such, an impressive array of HBOC’s have been in development, including PolyHeme (Northfield Laboratories, Evanston, IL), Hemolink (Hemosol, Mississauga, Ontario, Canada), HemAssist (Baxter Healthcare, Deerfield, IL), PHP (Apex Bioscience, Research Triangle Park, NC), Hemospan (Sangart, San Diego, CA), PEG-Hemoglobin (Enzon, Piscataway, NJ),

Factor	Human Plasma / Recombinant	Product Name	Manufacturer	Indications
Antithrombin III	Recombinant	ATryn	GTC	Hereditary antithrombin III deficiency
	Human Plasma	Thrombate	Grifols	
Protein C	Human Plasma	Ceprotin	Baxter	Severe congenital Protein C deficiency
Fibrinogen	Human Plasma	RiaSTAP	CSL Behring	Congenital fibrinogen deficiency
Factor VII (activated)	Recombinant	NovoSeven RT	Novo Nordisk	Hemophilia A or B with inhibitors; acquired hemophilia; congenital Factor VII deficiency
Factor VIII / von Willebrand factor complex	Human Plasma	Alphanate	Grifols	Hemophilia A; von Willebrand disease
		Humate-P	CSL Behring	
		Wilate	Octapharma	von Willebrand Disease
Factor VIII	Recombinant	ADVATE	Baxter	Hemophilia A
		Helixate FS	Bayer	
		Kogenate FS	Bayer	
		Recombinate	Baxter	
		Xyntha	Pfizer	
	Human Plasma	HEMOFIL M	Baxter	
		Koate-DVI	Grifols	
Factor IX	Recombinant	Monoclate-P	CSL Behring	Hemophilia B
		BeneFIX	Pfizer	
	Human Plasma	Rixubis	Baxter	
	AlphaNine SD	Grifols		
Factor VIII inhibitor bypassing activity (Factors II, IX, X, VIIa complex)	Human Plasma	Mononine	CSL Behring	Hemophilia A or B with inhibitors
		FEIBA VH	Baxter	
Factor IX complex (Factors II, IX, X, low Factor VII)	Human Plasma	BEBULIN	Baxter	Hemophilia B
		Profilnine SD	Grifols	
Prothrombin complex (Factors II, VII, IX, X, Protein C, Protein S, Antithrombin III)	Human Plasma	Kcentra	CSL Behring	Bleeding due to warfarin anticoagulation
Factor XIII	Recombinant	Tretten	Novo Nordisk	Congenital Factor XIII deficiency
	Human Plasma	Corifact	CSL Behring	

*As of March 2014; list may not be all-inclusive; consult manufacturer package inserts for further details on products.

GTC = GTC Biotherapeutics, Inc., Framingham, MA
 Grifols = Grifols Biologicals, Inc., Los Angeles, CA
 Baxter = Baxter Healthcare Corp., Westlake Village, CA
 CSL Behring = CSL Behring GmbH, Marburg, Germany
 Novo Nordisk = Novo Nordisk A/S, Bagsvaerd, Denmark
 Octapharma = Octapharma, Lachen, Switzerland
 Bayer = Bayer Healthcare, Tarrytown, NY
 Pfizer = Pfizer Inc., Philadelphia, PA

Table 1: Factor Concentrates Licensed in the United States*

Hemopure (Biopure, Cambridge, MA), Oxyglobin (Biopure), and Optro (Somatogen, Boulder, CO), but none have achieved FDA approval, though Hemopure has been approved for use in South Africa since 2001⁴⁵. In the end, it is likely that, if and when a so called blood substitute is approved by the FDA, the indications will be limited to extreme trauma or to situations in which blood transfusion may not be possible because of religious objection (as in Jehovah’s Witnesses who refuse transfusion with typical blood products) or because

of difficulty in finding compatible blood. However, other applications may include use as a cardioplegic oxygen solution for open heart surgery, for treatment of ischemia in myocardial infarction and stroke patients, and as sensitizers to oxygenate solid tumors for increased response to chemo- or radiotherapy⁴⁵. In other technology, artificial platelets (i.e., platelet substitutes) have been under development, but such development is still in the early stages⁴⁸. Pathogen-inactivated cellular components, such as Cerus Corporation’s

INTERCEPT Blood System (Cerus Corp., Concord, CA)⁴⁹ have also not been fully developed as of yet while solvent-detergent-treated plasma has recently been reintroduced to the U.S. market, albeit by a different manufacturer (Octaplas, Octapharma AG, Lachen, Switzerland)⁵⁰, after withdrawal of an earlier product, Plas+SD (VITEX, Watertown, MA) a decade ago after the FDA issued a Black Box warning contraindicating its use in liver transplant patients and those with severe liver disease (it must be noted here that Octaplas is manufactured using a different process and does not have such contraindication)⁵¹. Where technology perhaps has been most successful is in the development of factor concentrates. Both human plasma-derived and recombinant factor concentrates are available for use today to treat hemophilia and other coagulation disorders (see Table 1). Unfortunately, because human plasma-derived factor concentrates are manufactured from pooled plasma from thousands of donors, many of the early (1970's-1980's) hemophilia factor concentrates were tainted with HIV and hepatitis leading to the deaths of many hemophiliacs. By the mid 1980's, however, heat treatment and later other viral-inactivation steps such as solvent-detergent treatment were incorporated into the manufacturing processes of the plasma-derived concentrates along with improved donor screening and transmissible disease testing⁵². Recombinant factor VIII and factor IX products became available in the 1990's; since then, other recombinant factors have been approved (Table 1). These concentrates, though, are much more costly than conventional blood products (costing on average several thousand dollars per dose vs. several hundred dollars for a typical dose [several units] of transfused plasma). Yet more problematic is the clinical use of these products for the treatment of conditions for which there is little to no evidence of benefit and for which they were not intended for use by the FDA (i.e., off-label use). As an example, recombinant factor VIIa (NovoSeven RT, Novo Nordisk, Bagsvaerd, Denmark), intended for use in certain patients with hemophilia⁵³, was used for treatment of intracerebral bleeding after one study published in the *New England Journal of Medicine* showed promising data⁵⁴. Enthusiasm for such use diminished, however, after a follow-up study failed to demonstrate a survival benefit even though the study did demonstrate effectiveness of the product

in controlling the bleeding into the brain⁵⁵. Nevertheless, off-label use for recombinant factor VIIa and other concentrates persists with significant costs, uncertain benefits, and possible thromboembolic risks due to the high-clotting potency of these products.

7. Concluding remarks

Should all possible blood safety initiatives, no matter how remote the risk, be implemented at any cost?

Transfusion medicine continues to evolve with improvements in the quality and safety of blood components to minimize transfusion risks. Educating clinicians to follow appropriate transfusion practices under established blood management protocols is also of high importance, particularly since the accrediting agencies (AABB and TJC) will hold hospitals more accountable for their transfusion practices and in the light that newer, more potent, and more costly blood products, such the factor concentrates noted above, are becoming much more available and in demand. The search for a blood substitute continues but will likely have only limited applications when finally approved. Though many advances have been made in the field of transfusion medicine to date, a number of questions remain incompletely answered, such as the benefits vs. risks of more restrictive transfusion practices in higher-risk patients (i.e., those with underlying cardiovascular disease), the risks of transfusing older vs. fresher blood, the long term risks of blood transfusion on the immune system (TRIM), and the best practices to prevent established risks such as TRALI as well as questions about emerging risks. Further studies will be necessary and in some cases are ongoing to provide insight into these and other issues surrounding the transfusion of blood products. Ultimately though, we could not agree more with Menitove et al.⁵⁶ who advocate for a risk-based decision-making approach toward blood safety, noting that “some blood product safety initiatives cost more than 10 times the currently accepted threshold of up to \$100,000/quality-adjusted life year gained for other medical interventions” in the drive to attain a zero-risk blood supply.

Conflict of interest

There are no conflicts of interest.

References

1. US Department of Health and Human Services. The 2009 national blood collection and utilization survey report. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary for Health, 2011. Available from: <http://www.hhs.gov/ash/bloodsafety/2009nbcus.pdf>
2. Hogue CW, Goodnough LT, Monk TG. Perioperative myocardial episodes are related to hematocrit level in patients undergoing radical prostatectomy. *Transfusion* 1998; 38: 924-31. PMID: 9767742.
3. Wu W-C, Rathore MPH, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. *N Engl J Med.* 2001;345:1230-6. PMID: 11680442.
4. Kramer AH, Zygun DA. Anemia and red blood cell transfusion in neurocritical care. *Crit Care* 2009; 13: R89. PMID: 19519893.
5. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med.* 1999;340(6):409-17. PMID: 9971864.
6. Carson JL, Terrin ML, Magaziner J, et al. Transfusion trigger trial for functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS). *Transfusion* 2006; 46(12): 2192-206. PMID: 17176334.
7. Lacroix J, Hébert PC, Hutchison JS, et al. Transfusion strategies for patients in pediatric intensive care units. *N Engl J Med.* 2007;356(16): 1609-19. PMID: 17442904.
8. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. *N Engl J Med.* 2013;368:11-21 [Erratum, *N Engl J Med.* 2013;368:2341.] PMID: 23281973.
9. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. *Ann Intern Med.* 2012;157(1):49-58. PMID: 22751760
10. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: Red blood cell transfusion in adult trauma and critical care for the American College of Critical Care Medicine and the Eastern Association for the Surgery of Trauma Practice Management Workgroup. *Crit Care Med.* 2009;37(12):3124-57. PMID: 19773646.
11. Verlicchi F, Desalvo F, Zanotti G, et al. Red cell transfusion in orthopaedic surgery: a benchmark study performed combining data from different sources. *Blood Transfus.* 2011. PMID: 21627924.
12. National Heart, Lung and Blood Institute. What are the risks of a blood transfusion? <http://www.nhlbi.nih.gov/health/health-topics/topics/bt/risks.html> Accessed on March 5, 2014.
13. U.S. Food and Drug Administration. Guidance for Industry: Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection. June 2005. <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm074111.htm> Accessed on March 7, 2014.
14. U.S. Food and Drug Administration. Draft Guidance for Industry: Use of Serological Tests to Reduce the Risk of Transmission of *Trypanosoma cruzi* Infection in Whole Blood and Blood Components for Transfusion and Human Cells, Tissues, and Cellular and Tissue-Based Products. March 2009. <http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm125678.htm> Accessed on March 7, 2014.
15. Centers for Disease Control and Prevention. Bacterial contamination of platelets. <http://www.cdc.gov/bloodsafety/bbp/bacterial-contamination-of-platelets.html> Accessed on March 7, 2014.
16. Linden JV, Wong SJ, Chu FK, et al. Transfusion associated transmission of babesiosis in New York State. *Transfusion* 2000;40:285-9. PMID: 10738027.
17. Llewelyn CA, Hewitt PE, Knight RS, et al. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. *Lancet* 2004; 363: 417-21. PMID: 14962520.
18. Murphy EL, David Connor J, McEvoy P, et al. Estimating blood donor loss due to the variant CJD travel deferral. *Transfusion.* 2004;44(5):645-50. PMID: 15104643.
19. Féray C, Pawlotsky JM, Roque-Afonso AM, et al. Should we screen blood products for hepatitis E virus RNA? *The Lancet.* 2014;383:218. PMID: 24439737.
20. AABB. TRALI Risk Reduction Requirements in the 29th Edition of BBTS Standards. <https://www.aabb.org/sa/standards/Pages/trali-requirements-bbts-standards.aspx> Accessed on March 5, 2014.
21. Goldman M, Webert KE, Arnold DM, et al. Proceedings of a consensus conference: towards an understanding of TRALI. *Transfus Med Rev.* 2005;19(1):2-31. PMID: 15830325.
22. Strobel E. Hemolytic transfusion reactions. *Transfus Med Hemother.* Oct 2008; 35(5):346-353. PMID: 21512623.
23. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. *Transfus Med Rev.* 1992;6:116-123. PMID: 1591488.

24. Fierce Homeland Security. Security of radiological sources at medical facilities needs improvement, says GAO. <http://www.fiercehomelandsecurity.com/story/security-radiological-sources-medical-facilities-needs-improvement-says-gao/2012-09-13> Accessed on March 6, 2014.
25. Branch DR. Solving the dilemma of prevention of red cell alloimmunization. *Immunotherapy*. 2012; 9:903-905. PMID: 23046234.
26. AABB. National Hemovigilance Program Launches to Track Adverse Events Associated with Blood Transfusion. <http://www.aabb.org/pressroom/pressreleases/Pages/pr100218.aspx> February 18, 2010. Accessed on March 7, 2014.
27. Bolton-Maggs PHB, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. *Br J Haematol*. 2013;163:303-314. PMID: 24032719.28.
28. U.S. Food and Drug Administration. Guidance for Industry: Notifying FDA of Fatalities Related to Blood Collection or Transfusion. <http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm074947.htm> September 2003. Accessed on March 26, 2014.
29. New York State Department of Health. Transfusion/Blood Bank-related Incident Report. http://www.wadsworth.org/labcert/blood_tissue/forms/doh3336.pdf Accessed on March 26, 2014.
30. New Jersey Department of Health. Transfusion Reaction Report. <http://www.state.nj.us/health/forms/cl-44.dot> Accessed on March 26, 2014.31.ICCBBA. What is ISBT 128? <http://www.iccbba.org/home/isbt-128-basics/what-is-isbt-128> Accessed on March 1, 2014.
32. French Agency for the Safety of Health Products. Analysis of the risk of transmission of variant of Creutzfeldt-Jakob disease by health products and by tissues and fluids of human origin; update of findings of ad hoc group report of December 2000. Feb 2004. http://ansm.sante.fr/var/ansm_site/storage/original/application/2906328b3b0e08c665a7c7b0e5c42020.pdf Accessed on March 5, 2014.
33. Blumberg N, Heal JM. Blood transfusion immunomodulation. The silent epidemic. *Arch Pathol Lab Med*. 1998;122:117-8. PMID: 9499352.
34. Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. *N Engl J Med*. 2008; 358: 1229-39. PMID: 18354101.
35. Arinsburg SA, Skerrett DL, Friedman MT, Cushing M. A survey to assess transfusion medicine education needs for clinicians. *Transfus Med*. 2012;22:44-51. PMID: 22141339.
36. Friedman MT. Blood transfusion practices: a little consistency please. *Blood Transfus*. 2011;9:362-5. PMID: 21627918
37. AABB. Patient blood management. <http://www.aabb.org/resources/bct/pbm/Pages/default.aspx> Accessed on March 3, 2014.
38. The Joint Commission. New patient blood management program certification proposed by Joint Commission. <http://www.supportingsaferhealthcare.com/2013/08/new-patient-blood-management-certification-program-proposed-by-joint-commission/> Accessed on March 3, 2014.
39. The Joint Commission. *Implementation Guide for The Joint Commission Patient Blood Management Performance Measures*. Oak Brook Terrace, IL: The Joint Commission; 2011:14-17. Available at: http://www.jointcommission.org/assets/1/6/pbm_implementation_guide_20110624.pdf. Accessed on March 3, 2014.
40. Friedman MT, Ebrahim A. Adequacy of physician documentation of red blood cell transfusion and correlation with assessment of transfusion appropriateness. *Arch Pathol Lab Med*. 2006; 130:474-479. PMID: 16594741.
41. De Leon EM, Szallasi A. "Transfusion indication RBC (PBM-02)": gap analysis of a Joint Commission Patient Blood Management Performance Measure at a community hospital. *Blood Transfus*. 2014; 12 Suppl 1: s187-90:187-190. PMID: 23149139.
42. Friedman M, Arja W, Batra R, Daniel S, et al. Informed consent for blood transfusion: What Do Medicine Residents Tell? What Do Patients Understand? *Am J Clin Pathol*. 2012;138:559-565. PMID: 23010711.
43. Institute of Medicine Committee on Quality of Health Care in America. *Crossing the Quality Chasm: A New Health System for the 21st Century*. Washington, DC: National Academies Press; 2001.
44. Spahn DR. Blood substitutes. Artificial oxygen carriers: Perfluorocarbon emulsions. *Crit Care*. 1999;3:R93-R97. PMID: 11094488.
45. Dong Q, Stowell CP. Blood substitutes. What they are and how they might be used. *Am J Clin Pathol*. 2002;118(Suppl 1):S71-S80. PMID: 14569814.
46. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. *British Medical Bulletin*. 1999;55:277-298. PMID: 10695091.
47. Alayash AI. Blood substitutes: why haven't we been more successful? *Trends in Biotechnology*. 2014;4:177-185. PMID: 24630491.
48. Kim HW, Greenburg AG. Toward 21st century blood component replacement therapeutics: artificial oxygen carriers, platelet substitutes, recombinant clotting factors, and others. *Artif Cells Blood Substit*

- Immobil Biotechnol.* 2006;34:537-550. PMID: 17090427.
49. Cerus Press Release Details. Cerus and Grifols to collaborate on INTERCEPT Red Cell kit development. Cerus Corporation, 6/2/2009. <http://www.cerus.com/Investors/Press-Releases/Press-Release-Details/2009/Cerus-and-Grifols-to-Collaborate-on-INTERCEPT-Red-Cell-Kit-Development/default.aspx> Accessed on March 28, 2014.
 50. Hellstern P, Solheim BG. The use of solvent/detergent treatment in pathogen reduction of plasma. *Transfuse Med Hemother.* 2011;38:65-70. PMID: 21779207.
 51. U.S. Food and Drug Administration. Safety Alert: PLAS+SD (Pooled Plasma, (Human) Solvent Detergent Treated). March 29, 2002. <http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155086.htm> Accessed on March 28, 2014.
 52. Lusher JM. Hemophilia: from plasma to recombinant factors. American Society of Hematology. <http://www.hematology.org/publications/50-years-in-hematology/4737.aspx> Accessed on March 27, 2014.
 53. Novo Nordisk. NovoSeven RT prescribing information. <http://www.novo-pi.com/novosevenrt.pdf> Accessed on March 6, 2014.
 54. Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. *N Engl J Med.* 2005;352:777-785. PMID: 15728810.
 55. Mayer SA, Brun NC, Begtrup K. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. *N Engl J Med.* 2008; 358: 2127-2137. PMID: 18480205.
 56. Menitove JE, Leach Bennett J, Tomasulo P, Katz LM. How safe is safe enough, who decides and how? From a zero-risk paradigm to a risk-based decision making. *Transfusion.* 2014;54:753-757. PMID: 24617628.

DISCOVERIES is a peer-reviewed, open access, online, multidisciplinary and integrative journal, publishing high impact and innovative manuscripts from all areas related to MEDICINE, BIOLOGY and CHEMISTRY; © 2014, Applied Systems